The Houston- and Slovenia-based data firm wants to boot scientists off Excel spreadsheets and onto its flexible, proprietary platform for data management.
In recently published work, the researchers combined RNA-seq, proteomics, and metabolomics to study mechanisms of action of the chemotherapeutic cisplatin.
The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.
The company is partnering with three outside parties, including Thermo Fisher, to beta test the technology, which could improve mass spec throughput and sensitivity.
SMiLE-seq combines antibody arrays, mechanical trapping, and next-generation sequencing readouts to provide a new platform for characterizing DNA-protein interactions.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.